Navigation Links
Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
Date:11/2/2010

60;Adult enrollment in the study has closed; pediatric enrollment remains open.

"We are pleased with the interim results of the switchover trial to taliglucerase alfa," said Dr. David Aviezer, the Company's President and Chief Executive Officer.  "Through our Phase III pivotal and extension trial, pediatric study in naïve patients, switch–over trial, expanded access and named patient programs, ATU program in France and supply agreement in Brazil, we are generating a robust clinical database for taliglucerase alfa."

Taliglucerase alfa is under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Action (PDUFA) date scheduled for February 25, 2011.

About ProtalixProtalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. Protalix's ProCellEx™ presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. The Company's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

Safe Harbor StatementTo the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
2. Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
3. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
4. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
5. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
8. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
9. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
10. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
11. Oxygen Biotherapeutics, Inc. Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Eisai ... announced today that an article based on post-hoc analyses from ... Weight Loss While on Lorcaserin, Diet, and Exercise as a ... the online issue of Obesity , the official peer ... analyses was to identify whether there is an early treatment ...
(Date:7/30/2014)... 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), ... its expertise in opioid antagonists, announced today that ... prominent international research and development foundation. ... research-based initiatives, including those addressing health issues. Lightlake ... delivery of naloxone that could widely expand its ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... April 29 Wellcore Corporation, a Silicon Valley-based ... safety, begins shipping its highly anticipated Wellcore system today. ... live more active, independent lives, the Wellcore system offers ... will work outside of the home, unlike other fall ...
... on pharma industry , , , ... two whistleblower lawsuits that is being settled as part of Ortho-McNeil-Janssen Pharmaceuticals Inc.,s and Ortho-McNeil Pharmaceutical LLC,s ... northern Virginia . , , , ... , , ...
Cached Medicine Technology:The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available 2The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available 3Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 2Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 3Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 4
(Date:7/30/2014)... is being financially exploited often by their own ... poor and black people. It merits the scrutiny of ... about the dignity and well-being of older Americans, says ... the US. She led one of the largest American ... appear in the Journal of General Internal Medicine ...
(Date:7/30/2014)... A survey of beds within a large teaching hospital in ... with dimensional standards put in place to minimise the risk ... Age and Ageing , therefore emphasises the need for careful ... as well as the need for monitoring and maintenance of ... devices to prevent people falling from bed. However, although the ...
(Date:7/30/2014)... The report entitled “Global Pulse Oximetry Market: ... market dynamics and changing trends in the global pulse ... market sizing of the global pulse oximetry market and ... the same. It further captures the global market share ... market. Further, the report discusses the domestic market of ...
(Date:7/30/2014)... 2014 Los Angeles cosmetic dentist ... treatments that can help patients create their dream smiles ... and gums form the foundation of smile confidence, but ... chips, misshapen teeth or stains may not interfere with ... appearance. The right cosmetic treatments can eliminate chips, erase ...
(Date:7/30/2014)... Building ENT and Allergy Associates (ENTA) ... practice in Westchester County takes the best of everything. ... underlying corporate structure and protocols, and a staff that ... leading Chief Financial Officer to help run it. According ... what it possesses. In fact, in the WCBJ’s July ...
Breaking Medicine News(10 mins):Health News:Older adults are at risk of financial abuse 2Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3
... upright walking of humans? The discovery of four ... (quadrupedality) may help us understand how humans, unlike other primates, ... legs, a scientist will tell the annual conference of the ... The quadrupedal families in Turkey previously attracted attention in 2005, ...
... those with normal version of particular gene respond well ... -- Colon cancer patients who have the normal version ... from a combination treatment that includes adding the targeted ... cancer patients have the normal, or "wild-type" form of ...
... Widely prescribed blood-boosters might stimulate malignant cells, hasten death, ... Drugs used widely to treat anemia in cancer patients ... individuals, but researchers report they may found a way ... may have a test to predict whether a patient ...
... prevent malignancies, study suggests , , SUNDAY, June 1 (HealthDay ... day have value in helping to prevent lung cancer. ... cox-2 inhibitor on the U.S. market, may reduce levels ... The team presented its findings Sunday at the American ...
... CHICAGO, June 1 The combination of two different ... according to a University of Pittsburgh Cancer Institute (UPCI) ... American Society of Clinical Oncology (ASCO) in Chicago. , ... UPCI combined two biotherapies treatments that stimulate the ...
... study says , , SUNDAY, June 1 (HealthDay News) -- People ... are much more likely than other people to develop certain ... a cancer of the lymph nodes, has a cure rate ... future risk of developing second cancers other than HD, according ...
Cached Medicine News:Health News:Genetic mutation linked to walking on all 4s 2Health News:Genetic mutation linked to walking on all 4s 3Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 2Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Young Hodgkin Survivors Face Later Risk of Second Cancers 2
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
... Kawesch-Lancaster Lasik speculum has wide ... to provide clearance for the ... retract the lids and lashes ... the microkeratome. The blades are ...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Angled 45 degrees....
Medicine Products: